Disease activity following pregnancy-related discontinuation of natalizumab in MS.
Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.
Kleerekooper I, et al. Among authors: de jong ba.
Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.
Neurol Neuroimmunol Neuroinflamm. 2017.
PMID: 29379823
Free PMC article.